IMMUNALYSIS CORPORATION
Device
Abbott Laboratories
Total Payments
$20,906
Transactions
12
Doctors
10
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $248.94 | 10 | 9 |
| 2023 | $20,650 | 1 | 0 |
| 2022 | $7.07 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,650 | 1 | 98.8% |
| Food and Beverage | $256.01 | 11 | 1.2% |
Payments by Type
Research
$20,650
1 transactions
General
$256.01
11 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prospective Specimen Collection from Self-reported Drug Users for the Design and Development of ARDx Drugs of Abuse Assay | Abbott Laboratories | $20,650 | 0 |
Top Doctors Receiving Payments for IMMUNALYSIS CORPORATION
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Somerset, NJ | $20,650 | 1 |
| , DC | Neurology | South Daytona, FL | $72.93 | 1 |
| , F.N.P | Family | Knoxville, TN | $47.47 | 2 |
| , MD | Specialist | Knoxville, TN | $23.74 | 1 |
| , PA-C | Physician Assistant | Knoxville, TN | $23.74 | 1 |
| , ARNP | Family | Knoxville, TN | $23.73 | 1 |
| , M.D | Internal Medicine | Spartanburg, SC | $15.91 | 1 |
| , M.D | Specialist | Anderson, SC | $13.81 | 1 |
| , M.D | Anesthesiology | Anderson, SC | $13.81 | 1 |
| , FNP-BC | Family | Seneca, SC | $13.80 | 1 |
| , M.D | Pain Medicine | Waxhaw, NC | $7.07 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $20,906
Product Information
- Type Device
- Total Payments $20,906
- Total Doctors 10
- Transactions 12
About IMMUNALYSIS CORPORATION
IMMUNALYSIS CORPORATION is a device associated with $20,906 in payments to 10 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $248.94 was paid across 10 transactions to 9 doctors.
The most common payment nature for IMMUNALYSIS CORPORATION is "Unspecified" ($20,650, 98.8% of total).
IMMUNALYSIS CORPORATION is associated with 1 research study, including "Prospective Specimen Collection from Self-reported Drug Users for the Design and Development of ARDx Drugs of Abuse Assay" ($20,650).